CDKN2C and prostate cancer: Alterations of the gene profile of LAMB2 and CDKN2C/p18(Ink4c), a CDK4 inhibitor, have been reported on the transition from prostatic intraepithelial neoplasia (PIN) to prostate cancer [597] (see also [333]).